Dose-dependent EEG effects of zolpidem provide evidence for GABAA receptor subtype selectivity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1251-1257

  Visser, S A G ^a,d   Wolters, F L C ^a   Van der Graaf, P H ^b   Peletier, L A ^c   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ELECTROENCEPHALOGRAM; EXPERIMENTAL MODEL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; GABA AGONISTS; MALE; MODELS, ANIMAL; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, GABA-A;

EID: 0037369870     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044859     Document Type: Article

References (25)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Control AC-19:716-723.
2. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291-313.
3. Benavides J, Peny B, Ruano D, Vitorica J, and Scatton B (1993) Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 604:240-250.
4. Crestani F, Martin JR, Mohler H, and Rudolph U (2000) Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131:1251-1254.
5. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, and Bartholini G (1986) Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658.
6. Gabrielsson J and Weiner D (2000) Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications, Swedish Pharmaceutical Press, Stockholm.
7. Gibaldi M and Perrier D (1982) Pharmacokineties, Marcel Dekker, New York.
8. A/benzodiazepine receptor subtypes. J Neurosci 15:6957-6962.
9. Mandema JW and Danhof M (1992) Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 23:191-215.
10. Mohler H, Fritschy JM, and Rudolph U (2002) A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300:2-8.
11. Mood AM, Graybill FA, and Boes DC (1974) Introduction to the Theory of Statistics. McGraw-Hill Book Company, Singapore.
12. Patat A, Trocherie S, Thebault JJ, Rosenzweig P, Dubruc C, Bianchetti G, Court LA, and Morselli PL (1994) EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology 114:138-146.
13. Perrault G, Morel E, Sanger DJ, and Zivkovic B (1988) The interaction between zolpidem and β-CMC: a clue to the identification of receptor sites involved in the sedative effect of zolpidem. Eur J Pharmacol 156:189-196.
14. A receptor subunit for benzodiazepine pharmacology. Nature (Lond) 338:582-585.
15. A/α1 receptors. Eur J Pharmacol 406:R9- R10.
16. A/benzodiazepine receptor complex in the rat nervous system. J Neurochem 58:485-493.
17. Sheiner L and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
18. A receptor subtypes. Pharmacol Rev 47:181-234.
19. A receptor subtypes. Trends Pharmacol Sci 21:411-413.
20. Tuk B, van Gool T, and Danhof M (2002) Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil and zolpidem with ethanol. J Pharmcokinet Pharmacodyn 29:235-250.
21. Van der Graaf PH and Danhof M (1997) Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35:442-446.
22. A receptor in vivo. J Pharmacol Exp Ther 303:616-626.
23. Visser SAG, Smulders CJGM, Reijers BPR, Van der Graaf PH, Peletier LA, and Danhof M (2002a) Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration dependent hysteresis and biphasic EEG effects of alphaxalone in rats. J Pharmacol Exp Ther 302:1158-1167.
24. A receptor modulators: in vivo-in vitro correlations. J Pharmacol Exp Ther 304:88-101
25. Yano Y, Beal SL, and Sheiner L (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192.